title: Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.
abstract: The prognostic value of ferritin level at diagnosis in AML patients is unknown. We studied 162 younger AML patients with intermediate-risk cytogenetics who received intensive chemotherapy. The median ferritin level at diagnosis was 633 μg/L and 128 (79%) patients had a ferritin level above the upper normal limit. Hyperferritinemia was significantly associated with a higher cumulative incidence of relapse as well as poorer disease-free and overall survival. In multivariate analysis, hyperferritinemia remained an independent poor prognosis factor. The level of ferritin at diagnosis has a major impact on relapse suggesting a link between inflammation, oxidative stress and chemoresistance in AML.
authors.affiliation: Service d'Hématologie Clinique, CHU Amiens, Amiens Cedex 1, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Lebon
authors.affiliation: Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France.
authors.forename: François
authors.initials: F
authors.lastname: Vergez
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Bertoli
authors.affiliation: Laboratoire d'Hématologie, CHU Amiens, Amiens Cedex 1, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Harrivel
authors.affiliation: Service d'Hématologie Clinique, Institut Gustave Roussy, Villejuif, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: De Botton
authors.affiliation: Service d'Hématologie Clinique, Institut Gustave Roussy, Villejuif, France.
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Micol
authors.affiliation: Service d'Hématologie Clinique, Université de Picardie Jules Verne, CHU Amiens, Amiens Cedex 1, France. Electronic address: marolleau.jean-pierre@chu-amiens.fr.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Marolleau
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France. Electronic address: recher.christian@iuct-oncopole.fr.
authors.forename: Christian
authors.initials: C
authors.lastname: Récher
mesh_terms: D000293:Adolescent; D000328:Adult; D020732:Cytogenetic Analysis; D005260:Female; D005293:Ferritins / Q000097:blood*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000235:genetics / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000235:genetics / Q000401:mortality*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D005293:Ferritins
keywords: Acute myeloid leukemia; Ferritin; Leukemia; Prognosis